| Reference |
Design |
N |
Duration (weeks) |
Study name/Comment |
| Arribas et al. [40] |
Randomized, open-label, non-inferiority |
511 |
96-144 |
— |
| Calmy et al. [32] |
Retrospective |
5,636 |
218 (4.2 years) |
ATHENA, SHCS, HOMER cohorts |
| Cohen et al. [23] |
Phase 3, randomized, double-blind, double-dummy, non-inferiority |
338 |
48 |
THRIVE |
| Daar et al. [20] |
Randomized, equivalence |
922 |
138 |
ACTG 5202 |
| DeJesus et al. [42] |
Randomized, controlled, open-label |
203 |
48 |
— |
| DeJesus et al. [44] |
Phase 4, randomized |
76 |
48 |
NEWART |
| Fätkenheuer et al. [39] |
Randomized, double-blind, non-inferiority |
157 |
48 |
SENSE |
| Gathe et al. [26] |
Randomized, double-blind, double-dummy, parallel group |
1168 |
48 |
VERxVE |
| Hodder et al. [36] |
Phase 3b, open-label |
207 |
48 |
GRACE |
| Katlama et al. [35] |
Phase 3, randomized, double-blind |
599 |
96 |
DUET-1 and -2 |
| Labarga et al. [33] |
Retrospective |
178 |
64 (16 months) |
— |
| Lockman et al. [51] |
Prospective, open-label |
500 |
48 weeks |
ACTG A5208/OCTANE |
| Molina et al. [22] |
Phase 3, randomized, double-blind, double-dummy, active-controlled |
344 |
48 |
ECHO |
| Mugavero et al. [52] |
Meta-analysis of completed trials ART-CC cohort vs ACTG 5095 and 5142 trials |
ACTG 5095 + ART-CC (n=5,363)
ACTG 5142 and ART-CC (n=8,710) |
24 and 48 weeks |
ACTG 5095
ACTG 5142
ART-CC chort |
| Podzamczer et al. [28] |
Randomized, open-label |
289 |
48 |
— |
| Post et al. [41] |
Randomized, open-label |
385 |
48 |
ASSERT |
| Pozniak et al. [24] |
Phase 2b, randomized |
89 |
96 |
— |
| Reliquet et al. [30] |
Retrospective |
592 |
624 (12 years) |
— |
| Riddler et al. [53] |
Prospective, open-label study |
757 |
112 weeks median follow-up |
|
| Rockstroh et al. [19] |
Phase 3, randomized, double-blind, non-inferiority |
282 |
156 |
STARTMRK |
Rodriguez-Arrondo
et al. [31] |
Retrospective |
229 |
312 (6 years) |
— |
| Sierra-Madero et al. [21] |
Double-blind, double-dummy, non-inferiority |
361 |
96 |
MERIT |
| Soriano et al. [27] |
Randomized, open-label, non-inferiority |
383 |
48 |
ARTEN |
| Vallecillo et al. [34] |
Retrospective |
123 |
48 |
— |
van den Berg-Wolf
et al. [25] |
Randomized, strategy |
111 |
260 (5 years) |
FIRST |
| Weberschock et al. [29] |
Prospective, non-randomized |
70 |
72 |
TENOR |
| Wilkin et al. [43] |
Phase 2b, randomized |
89 |
192 |
— |
|
